Acacia Research (NASDAQ:ACTG - Get Free Report) released its earnings results on Wednesday. The business services provider reported $0.13 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.22, FiscalAI reports. Acacia Research had a negative net margin of 8.53% and a negative return on equity of 2.81%. The company had revenue of $114.56 million during the quarter, compared to analysts' expectations of $49.50 million.

• How to Screen for Cash Value Stocks in a Bear Market

Here are the key takeaways from Acacia Research's conference call:

• Q2 results were strong, with revenue of $114.6 million, total company adjusted EBITDA of $17.3 million, and adjusted net income of $12.8 million, or $0.13 per diluted share.
• Acacia ended the quarter with $334.6 million in cash, securities, and loans receivable and no parent-company debt, providing flexibility for acquisitions and investment in existing businesses. Management said its acquisition pipeline is active, particularly for bilateral and distressed opportunities.
• Benchmark delivered record revenue of $20.5 million, $9.8 million of adjusted EBITDA, and $6.5 million of free cash flow; management is evaluating additional wells and expects future drilling economics to be similar to the Cherokee development.
• The intellectual property platform generated approximately $60.6 million in licensing revenue, primarily from a Wi-Fi 6 settlement, but management cautioned that licensing revenue is episodic and is reduced by payments to counsel, inventors, and partners; settlement cash was received after quarter-end.
• Acacia fully wrote down its MalinJ1 investment following liquidity problems at Mycovia, although it is exploring a transaction that could provide direct ownership in Mycovia; any recovery depends on financing and uncertain FDA milestones for VIVJOA.

Acacia Research Stock Performance

Shares of ACTG traded down $0.07 during midday trading on Wednesday, reaching $4.54. 681,053 shares of the stock were exchanged, compared to its average volume of 271,890. The company has a debt-to-equity ratio of 0.10, a current ratio of 8.56 and a quick ratio of 8.09. Acacia Research has a twelve month low of $3.12 and a twelve month high of $5.27. The business's 50-day moving average price is $4.61 and its 200 day moving average price is $4.55. The company has a market capitalization of $438.52 million, a price-to-earnings ratio of -25.22 and a beta of 0.45.

Institutional Investors Weigh In On Acacia Research

A number of hedge funds and other institutional investors have recently modified their holdings of ACTG. AQR Capital Management LLC bought a new stake in shares of Acacia Research in the 1st quarter valued at approximately $35,000. Zions Bancorporation National Association UT acquired a new position in shares of Acacia Research during the fourth quarter valued at $38,000. Occudo Quantitative Strategies LP bought a new stake in shares of Acacia Research during the 4th quarter worth about $49,000. Abel Hall LLC bought a new stake in shares of Acacia Research during the 4th quarter worth about $51,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Acacia Research in the 3rd quarter worth approximately $65,000. 86.69% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Acacia Research from a "hold (c-)" rating to a "sell (d-)" rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $6.00.

View Our Latest Analysis on Acacia Research

Acacia Research Company Profile

(Get Free Report)

Acacia Research Corporation is a publicly traded patent licensing company based in New York City. The firm specializes in acquiring patented technologies through a network of wholly owned subsidiaries and seeking licensing agreements or settlements with companies that utilize those technologies. Since its founding in 1993, Acacia has built a business model centered on identifying innovative inventions and monetizing them through patent enforcement and strategic partnerships.

The company's activities span a broad range of technology sectors, including life sciences, medical devices, software, telecommunications and consumer electronics.

Recommended Stories

• Five stocks we like better than Acacia Research
• SpaceX: Love the Company, But the Stock Is a Harder Call
• Ulta's Growth Is Real, But So Are the Risks
• BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
• Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Acacia Research Right Now?

Before you consider Acacia Research, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acacia Research wasn't on the list.

While Acacia Research currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here